Abstract
Introduction. EMS treatment of status epilepticus improves outcomes, but the benzodiazepine best suited for EMS use is unclear, given potential high environmental temperature exposures. Objective. To describe the degradation of diazepam, lorazepam, and midazolam as a function of temperature exposure and time over 120 days of storage on active EMS units. Methods. Study boxes containing vials of diazepam, lorazepam, and midazolam were distributed to 4 active EMS units in each of 2 EMS systems in the southwestern United States during May-August 2011. The boxes logged temperature every minute and were stored in EMS units per local agency policy. Two vials of each drug were removed from each box at 30-day intervals and underwent high-performance liquid chromatography to determine drug concentration. Concentration was analyzed as mean (and 95%CI) percent of initial labeled concentration as a function of time and mean kinetic temperature (MKT). Results. 192 samples were collected (2 samples of each drug from each of 4 units per city at 4 time-points). After 120 days, the mean relative concentration (95%CI) of diazepam was 97.0% (95.7-98.2%) and of midazolam was 99.0% (97.7-100.2%). Lorazepam experienced modest degradation by 60 days (95.6% [91.6-99.5%]) and substantial degradation at 90 days (90.3% [85.2-95.4%]) and 120 days (86.5% [80.7-92.3%]). Mean MKT was 31.6°C (95%CI 27.1-36.1). Increasing MKT was associated with greater degradation of lorazepam, but not midazolam or diazepam. Conclusions. Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments. Lorazepam experienced significant degradation over 120 days and appeared especially sensitive to higher MKT exposure.
| Original language | English |
|---|---|
| Pages (from-to) | 368-374 |
| Number of pages | 7 |
| Journal | Prehospital Emergency Care |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 1 2014 |
Bibliographical note
Funding Information:This work was conducted as part of the RAMPART trial, which was supported by awards from the National Institute of Neurological Disorders and Stroke (NINDS) (U01NS056975 and U01NS059041); the National Institutes of Health Office of the Director CounterACT Program; and the Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response.
Funding
This work was conducted as part of the RAMPART trial, which was supported by awards from the National Institute of Neurological Disorders and Stroke (NINDS) (U01NS056975 and U01NS059041); the National Institutes of Health Office of the Director CounterACT Program; and the Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response.
| Funders | Funder number |
|---|---|
| Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response | |
| National Institutes of Health Office of Research on Women's Health | |
| Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council | U01NS059041, U01NS056975 |
| Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council |
Keywords
- Benzodiazepines
- Emergency medical services
- Temperature
ASJC Scopus subject areas
- Emergency Medicine
- Emergency